Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Targeting Disease-Causing Cells: RheumMadness 2022 Chimeric Antigen Receptor T Cells Scouting Report

Mass General Hospital Rheumatology Fellowship Program: Guy Katz, MD; Ian Cooley, MD; Duncan Moore, MD; Jacquelyn Nestor, MD, PhD; & Steven Witte, MD, PhD  |  Issue: May 2022  |  February 8, 2022

Editor’s note: RheumMadness is the place for everyone crazy about rheumatology to connect, collaborate, compete and learn together. During RheumMadness, rheumatology concepts represent teams that compete against each other in a tournament, much like basketball teams do in the NCAA’s March Madness tournament. In a series for The Rheumatologist, readers will get a chance to read the scouting reports for each concept team. These reports are written by rheumatology fellows from 13 programs throughout the U.S.

Don’t forget to submit your RheumMadness 2022 bracket by March 25. The more your picks match those of our Blue Ribbon Panel of rheumatologists, the more points you get. Learn more about the panel and how the brackets work online.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Connect with RheumMadness by subscribing to the podcast and joining the conversation on Twitter, #RheumMadness. Learn more on the RheumMadness website. 

Region: Cells

Team: CAR-T Cells

Chimeric antigen receptor T (CAR-T) cells are made by combining T cell receptor constant variant domains and antibody variable domains. Anti-CD19-targeted CAR-T cells have been shown to be a power forward in the destruction of B cell malignancies, even in patients boxed out of other therapies.

Inspired by this success with CAR-T cell therapy in hematologic malignancies, CD19 CAR-T cell therapy is actively being recruited as the next MVP for B cell depletion therapy in patients with autoimmune disease. It’s hypothesized this elite therapy can better access—within lymphatic organs and inflamed tissues for example—and persistently deplete autoreactive B cells than current players, such as rituximab.

Given that CD19 is expressed during all major states of B cell maturation, it’s speculated that anti-CD19 therapy may lead to depletion of pro-B cell plasmablasts secreting pathologic autoantibodies and some plasma cells. A case report by Mougiakakos et al. in which a severe case of refractory systemic lupus erythematosus (SLE) was swiftly knocked out by CD19 CAR-T cell therapy illustrates the immense power of this emerging, immunosuppressive all-star in the treatment of rheumatic diseases.1

CAR-T cell therapies have been tested in mouse models for type 1 diabetes, lupus, multiple sclerosis, colitis and other diseases with at least some measurable benefit. Additionally, pre-clinical CAR-T studies have been completed or are ongoing for rheumatoid arthritis (RA), SLE and systemic sclerosis. Other potential applications include CAR-T cells expressing citrullinated antigens to target anti-citrulline B cells to treat RA and CAR-T reg cell therapies.2

Implications

CAR-T cells represent a major shift in the nature of therapeutics for rheumatology—possibly more profound than the addition of biologic disease-modifying anti-rheumatic drugs (DMARDs) to the conventional synthetic DMARD playbook in the late 1990s and early 2000s.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsResearch Rheum Tagged with:CAR-T cell therapycellschimeric antigen receptor T (CAR-T) cellsRheumMadness

Related Articles
    Tasha Art; PureSolution / shutterstock.com

    RheumMadness: An Educational Tournament

    July 15, 2021

    RheumMadness is an online collaborative learning experience created to educate trainees, rheumatologists and the wider medical community about recent advances and important concepts in rheumatology. The project is funded by the Rheumatology Research Foundation Clinician Scholar Educator (CSE) Award and modeled after NephMadness, an educational initiative of the American Journal of Kidney Diseases (AJKD) that…

    An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

    February 8, 2022

    According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.

    Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report

    March 2, 2022

    Rheumatologists play a critical role in the reproductive health of their patients, but only half of rheumatologists currently ask their patients about reproductive health or family planning issues. A new guideline seeks to change that.

    Get the Picture: RheumMadness 2022 PET-CT in Large Vessel Vasculitis Scouting Report

    February 14, 2022

    With both impressive sensitivity and specificity in capturing active large vessel vasculitis, a positron emission tomography (PET) scan is a potential tool for determining disease activity and predicting relapse in patients with large vessel vasculitis.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences